Back to Results

Cerus Corporation (CERS)

Featured in High-Growth Small-Cap Stocks Small-Cap Stocks

Cerus Corporation (NASDAQ-CERS) is a healthcare company whose common stock trades on NASDAQ. The Cerus Corporation security is described here as common equity, reflecting an ownership interest in the issuer rather than a fund, debt instrument, or other listed product. The company’s business is centered on blood safety technologies used in the processing of donated blood components. Its work relates to reducing contamination risk in transfusion-related materials and supporting pathogen reduction across selected blood products. As a healthcare equipment and supplies name, Cerus is associated with specialized medical technology rather than broad consumer health products.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CERS
$3.33
4.2% Upside
Fair
$4.67
46.1% Upside
Undervalued
Good
—
—
—
0.0%
July 30, 2026
-67.5x
9.5x
3.0x
631.2 M
661.9 M
13.4%
91.3%
-3.1
—
12.8%
Send a message
Valuation • Fair Value

Cerus Corporation (NASDAQ-CERS) Fair Value by Valuation Model

Compare the primary fair value estimate for Cerus Corporation (NASDAQ-CERS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.33

Estimated upside of 4.2% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.23

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$2.43

Comparable-company valuation reference.

Analyst Price Target

$4.67

Analysts imply upside of 46.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Cerus Corporation (NASDAQ-CERS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Cerus Corporation (NASDAQ-CERS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

216.6 M

Current operating scale indicator.

Revenue Forecast

230 M

Forward revenue estimate.

EBITDA

-1.616 M

Current operating profitability reference.

EBITDA Forecast

19.021 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cerus Corporation (NASDAQ-CERS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cerus Corporation (NASDAQ-CERS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.64

No elevated caution signal from this screen.

Altman Z-Score

-3.1

Lower score that deserves closer risk review.

FCF / Net Income

12.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cerus Corporation (NASDAQ-CERS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cerus Corporation (NASDAQ-CERS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Cerus Corporation (NASDAQ-CERS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cerus Corporation (NASDAQ-CERS) Stock Forecast & Technical Outlook

Review Cerus Corporation (NASDAQ-CERS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cerus Corporation (NASDAQ-CERS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cerus Corporation (NASDAQ-CERS) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cerus Corporation (NASDAQ-CERS) Stock FAQ

Quick answers about Cerus Corporation (NASDAQ-CERS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.33
Estimated upside 4.2%
Valuation Rating
Undervalued
Estimated upside of 4.2%
Analyst Target
$4.67
Implied upside 46.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for Cerus Corporation (NASDAQ-CERS) is $3.33. This implies an estimated upside of 4.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.2% versus the current market price.

The available analyst price target for Cerus Corporation (NASDAQ-CERS) is $4.67. The analyst target implies estimated upside of 46.1%.

The current financial health read for Cerus Corporation (NASDAQ-CERS) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cerus Corporation (NASDAQ-CERS) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Cerus Corporation (NASDAQ-CERS) is -67.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cerus Corporation is 631.2 M.

The current enterprise value listed for Cerus Corporation is 661.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cerus Corporation is NASDAQ-CERS, and the stock is listed on NASDAQ.

Cerus Corporation (NASDAQ-CERS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cerus Corporation is 13.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cerus Corporation is 91.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
Omnicell Inc (OMCL) Omnicell Inc (OMCL)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)